PolyPeptide raises 2026 guidance on 42% H1 metabolics growth
Metabolics segment drives strong first-half revenue growth, prompting upward revision to full-year outlook.
PolyPeptide Group raised its full-year guidance after the metabolics division delivered 42% revenue growth in the first half of 2026, the company said in a presentation slide deck.
The Swiss-based biopharmaceutical contract development and manufacturing organization (CDMO) reported that metabolics revenue reached CHF 125 million in H1 2026, up from CHF 88 million in the same period last year. The segment’s performance outpaced the broader company, which saw total H1 revenue of CHF 310 million, a 28% increase year-over-year.
Driven by rising demand for metabolic disorder treatments, PolyPeptide’s metabolics pipeline expanded with multiple client projects reaching commercialization stages. The company attributed the growth to increased outsourcing by pharmaceutical partners and a shift toward specialized manufacturing for rare metabolic diseases.
In response to the strong H1 performance, PolyPeptide revised its 2026 revenue guidance to a range of CHF 650 million to CHF 680 million, up from the prior forecast of CHF 600 million to CHF 630 million. The upward adjustment reflects confidence in sustained demand across its metabolics and other core segments, including peptides and complex APIs.
Analysts noted that the guidance hike signals robust market conditions for CDMOs specializing in metabolic therapies, though they cautioned that macroeconomic pressures could temper growth in the second half of the year.
PolyPeptide’s shares were indicated higher in pre-market trading, reflecting investor optimism following the guidance upgrade.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →